Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH-1105 Phase 1 Safety and PK Study
NCT06432647Phase 1Completed
- Sponsor
- LeonaBio
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing ATH-1105 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Severity of Treatment-Emergent Adverse Events. Started Apr 2024; status: completed.
02
Drugs
ATH-1105
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06432647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432647.